SCHEMBL966416

SCHEMBL966416

N#Cc1nc(N2CCCCS2(O)O)c2cccnc2c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALCA P06881 6/20 0.46
COMT P21964 4/20 0.35
KDM4E B2RXH2 4/20 0.35
L3MBTL1 Q9Y468 4/20 0.35
TP53 P04637 3/20 0.35
ALOX12 P18054 3/20 0.35
HTT P42858 3/20 0.35
NPC1 O15118 2/20 0.35
LMNA P02545 2/20 0.35
ALOX15 P16050 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
METAP2 P50579 1/20 0.35
CYP1A2 P05177 1/20 0.35
HSP90AA1 P07900 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
MPI P34949 1/20 0.35
RAB9A P51151 1/20 0.35
ATM Q13315 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL966418 0.88 CALCA (0.59) CALCACOMTKDM4EL3MBTL1TP53
SCHEMBL967472 0.82 KCNMA1 (0.43) COMTKDM4EL3MBTL1TP53ALOX12
SCHEMBL4769035 0.80 CALCA (0.60) CALCACOMTKDM4EL3MBTL1TP53
SCHEMBL4067974 0.77 CALCA (0.56) CALCACOMTKDM4EL3MBTL1TP53
SCHEMBL968122 0.77 CALCA (0.64) CALCACOMTKDM4EL3MBTL1TP53
SCHEMBL7258799 0.76 CALCA (0.56) CALCACOMTKDM4EL3MBTL1TP53
SCHEMBL966563 0.74 COMT (0.38) CALCACOMTKDM4EL3MBTL1TP53
SCHEMBL7262571 0.73 CALCA (0.53) CALCACOMTKDM4EL3MBTL1TP53
SCHEMBL967712 0.71 CALCA (0.52) CALCACOMTKDM4EL3MBTL1TP53
SCHEMBL968369 0.71 KDM4E (0.49) COMTKDM4EL3MBTL1TP53ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003794-A1 Naphthyridine Integrase Inhibitors GSK LLC 2011-01-06 US disclosed
US-7812016-B2 Naphthyridine integrase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2010-10-12 US disclosed
EP-1622615-A4 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-02-18 EP disclosed
US-20070142365-A1 Naphthyridine integrase inhibitors GSK LLC 2007-06-21 US disclosed
EP-1622615-A2 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-02-08 EP disclosed
WO-2004101512-A2 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003794-A1 Naphthyridine Integrase Inhibitors PCNA, SAMHD1, NTPCR CALCA 4461/4885COMT 1043/4885KDM4E 2029/4885
US-20070142365-A1 Naphthyridine integrase inhibitors PCNA, SAMHD1, NTPCR CALCA 4461/4885COMT 1043/4885KDM4E 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.